Special dialysis for kidney failure in newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a special type of dialysis that filters out harmful proteins from the blood in people with newly diagnosed multiple myeloma and sudden kidney failure. It aims to see if this treatment helps the kidneys recover and improves overall outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have just been diagnosed with multiple myeloma.
- Your kidneys have suddenly failed enough that you need dialysis (your kidney function is very low).
- Doctors believe the kidney damage is caused by myeloma proteins, not by other things like blockage or high calcium.
- You have high levels of free light chains in your blood (a protein that damages kidneys).
- You do not have long-term kidney disease (kidney problems lasting more than 3 months), unstable blood pressure, active bleeding, or recent heart/head problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests a personalized treatment approach for people aged 65 and older with newly diagnosed multiple myeloma. The goal is to tailor therapy based on each patient's level of frailty, which could help improve outcomes and reduce side effects.
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.